BioTuesdays
Gracell Biotechnologies

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...

Annovis Logo

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...

Myomo

AGP ups Myomo to buy; PT $4.60 from $2

Alliance Global Partners upgraded Myomo (NYSE:MYO) to “buy” and raised its price target to $4.60 from $2. The stock was quoted at $1.85 midday on Nov.8. Myomo develops and markets the MyoPro product line of lightweight...

Adlai-Nortye-Logo

Cantor starts Adlai Nortye at OW; PT $30

Cantor Fitzgerald launched coverage of Adlai Nortye (NASDAQ:ANL) with an “overweight” rating and price target of $30. The stock closed at $8.52 on Oct 24. The company is focused on the discovery and development of...

JMP starts Vigil Neuroscience at MO; PT $23

JMP Securities initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “market outperform” rating and price target of $23. The stock was quoted at $6.50 midday on Oct 18. Vigil is developing novel therapies for...

Spheric BioCantor starts Solid at OW; PT $5

Cantor Fitzgerald launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “overweight” rating and 12-month price target of $5. The stock closed at $2.76 on Sept. 22. Solid is using its gene therapy platform to...

Profound Medical

RJ ups Profound Medical to strong buy

Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...

Nanox-Imaging-Logo

AGP starts Nano-X Imaging at buy; PT $14.50

Alliance Global Partners initiated coverage of Nano-X Imaging (NASDAQ:NNOX) with a “buy” rating and price target of $14.50. The stock closed at $7.66 on Sept. 7. “Nano-X’s novel digital X-ray source has the potential to...

AGF starts Aspira Women’s Health at buy; PT $5.60

Alliance Global Partners initiated coverage of Aspira Women’s Health (NASDAQ:AWH) with a “buy” rating and price target of $5.60. The stock closed at $2.76 on Aug. 21. Aspira Women’s Health’s proprietary...

Leerink starts Turnstone Biologics at MP; PT $13

Leerink Partners initiated coverage of Turnstone Biologics (NASDAQ:TSBX) with a “market perform” rating and $13 price target. The stock closed at $11.73 on Aug. 14. “We see potential in Turnstone’s selected tumor...

Ladenburg cuts Salarius to neutral; removes PT

Ladenburg Thalmann downgraded Salarius Pharmaceuticals (NASDAQ:SLRX) to “neutral” from “buy” and removed its price target after the company disclosed it is exploring strategic alternatives and implement cost-cutting...

Quanterix Logo

Leerink ups Quanterix to OP; PT to $30

Leerink Partners upgraded Quanterix (NASDAQ:QTRX) to “outperform” from “market perform” and raised its price target to $30 from $25, citing strong evidence for its assays redevelopment effort. Analyst Puneet Souda...

Cantor starts Health Catalyst at OW; PT $16

Cantor Fitzgerald launched coverage of Health Catalyst (NASDAQ:HCAT) with an “overweight” rating and price target of $16, representing a 2024 enterprise value/revenue multiple of 2.3 times. The stock closed at $14.03 on...

Cantor starts Belite Bio at OW; PT $43

Cantor Fitzgerald launched coverage of Belite Bio (NASDAQ:BITR) with an “overweight” rating and a 12-month price target of $43. Belite listed its ADSs on NASDAQ in April 2022; they closed at $20.55 on July 27. Belite...

Aeglea-Bio-Logo

Stifel starts Aeglea Bio at buy; PT 90 cents

Stifel initiated coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and price target of 90 cents. The stock closed at 59 cents on July 24. Aeglea is a biotechnology company that is now focused on the...